Subsequent Primary Malignancies Among Myelodysplastic Syndrome Patients Treated with or without Lenalidomide

被引：0
|
作者：
Rollison, Dana E. [1 ]
Shain, Kenneth H. [1 ]
Lee, Ji-Hyun [2 ]
Hampras, Shalaka S. [1 ]
Fisher, Kate [1 ]
Al Ali, Najla H. [1 ]
Padron, Eric [3 ]
Lancet, Jeff E. [1 ]
Olesnyckyj, Marta [4 ]
Kenvin, Laurie [4 ]
Knight, Robert D. [4 ]
Dalton, William [1 ]
List, Alan F. [1 ]
Komrokji, Rami [1 ]
机构：
[1] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA
[2] Univ New Mexico, Ctr Canc, Albuquerque, NM 87131 USA
[3] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA
[4] Celgene Corp, Summit, NJ USA
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Second Primary Malignancies in Newly Diagnosed Multiple Myeloma Patients Treated with Lenalidomide: Analysis of Pooled Data in 2459 Patients
    Palumbo, Antonio
    Larocca, Alessandra
    Zweegman, Sonja
    Lupparelli, Giulia
    Siniscalchi, Agostina
    Musto, Pellegrino
    Levin, Moshe
    Lokhorst, Henk
    Grammatico, Sara
    Catalano, Lucio
    Ria, Roberto
    Liberati, Anna Marina
    Patriarca, Francesca
    Benevolo, Giulia
    Falcone, Antonietta Pia
    van der Holt, Bronno
    Verelst, Sylvia
    Rossi, Davide
    Crippa, Claudia
    Bringhen, Sara
    Hajek, Roman
    Spencer, Andrew
    Boccadoro, Mario
    Sonneveld, Pieter
    BLOOD, 2011, 118 (21) : 455 - 455
  • [22] Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide
    Yuka Sugimoto
    Mikkael A Sekeres
    Hideki Makishima
    Fabiola Traina
    Valeria Visconte
    Anna Jankowska
    Andres Jerez
    Hadrian Szpurka
    Christine L O'Keefe
    Kathryn Guinta
    Manuel Afable
    Ramon Tiu
    Kathy L McGraw
    Alan F List
    Jaroslaw Maciejewski
    Journal of Hematology & Oncology, 5
  • [23] Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide
    Sugimoto, Yuka
    Sekeres, Mikkael A.
    Makishima, Hideki
    Traina, Fabiola
    Visconte, Valeria
    Jankowska, Anna
    Jerez, Andres
    Szpurka, Hadrian
    O'Keefe, Christine L.
    Guinta, Kathryn
    Afable, Manuel
    Tiu, Ramon
    McGraw, Kathy L.
    List, Alan F.
    Maciejewski, Jaroslaw
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2012, 5
  • [24] CYTOGENETIC FOLLOW-UP IN PATIENTS WITH IN MYELODYSPLASTIC SYNDROME TREATED WITH LENALIDOMIDE: IMPACT OF KARYOTYPING AND FLUORESCENCE IN SITU HYBRIDIZATION
    Goehring, G.
    Giagounidis, A.
    Hofmann, W.
    Buesche, G.
    Kreipe, H.
    Cazzola, M.
    Fenaux, P.
    Hellstrom-Lindberg, E.
    Schlegelberger, B.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 85 - 85
  • [25] Glycemic variability and subsequent malignancies among the population without diabetes
    Kobayashi, Daiki
    Noto, Hiroshi
    Takahashi, Osamu
    Shimbo, Takuro
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2020, 159
  • [26] LENALIDOMIDE TREATMENT IN 20 PATIENTS WITH MYELODYSPLASTIC SYNDROME (MDS). MULTICENTER REGISTRY
    Arrizabalaga, B.
    Del Orbe, R.
    Zamora, M.
    Ardanaz, M.
    Arguinano, J.
    Sirvent, M.
    Atucha, L.
    Atucha, J.
    Insunza, A.
    Montes, C.
    Campeny, A.
    HAEMATOLOGICA, 2013, 98 : 585 - 585
  • [27] Lenalidomide linked to low reporting rate of VTE in patients with myelodysplastic syndrome
    Reactions Weekly, 2009, 1244 (1) : 3 - 3
  • [28] Telomere shortening, clonal evolution and disease progression in myelodysplastic syndrome patients with 5q deletion treated with lenalidomide
    Goehring, G.
    Lange, K.
    Hofmann, W.
    Nielsen, K. V.
    Hellstrom-Lindberg, E.
    Roy, L.
    Morgan, M.
    Kreipe, H.
    Buesche, G.
    Giagounidis, A.
    Schlegelberger, B.
    LEUKEMIA, 2012, 26 (02) : 356 - 358
  • [29] Conventional and Molecular Cytogenetic Responses in Patients with Myelodysplastic Syndrome (MDS) with Deletion 5q Treated with Lenalidomide.
    Coutinho, Rita
    Costa, Dolors
    Carrio, Ana
    Vidal, Ana
    Belkaid, Mohammed
    Campo, Elias
    Montserrat, Emili
    Nomdedeu, Benet
    BLOOD, 2009, 114 (22) : 694 - 694
  • [30] Telomere shortening, clonal evolution and disease progression in myelodysplastic syndrome patients with 5q deletion treated with lenalidomide
    G Göhring
    K Lange
    W Hofmann
    K V Nielsen
    E Hellström-Lindberg
    L Roy
    M Morgan
    H Kreipe
    G Büsche
    A Giagounidis
    B Schlegelberger
    Leukemia, 2012, 26 : 356 - 358
12345